Hepatitis B

LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant…

– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis B virus surface antigen (HBsAg)…

Pune, India, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The global hepatitis B vaccine market size was USD 7.53 billion in 2021. The market is projected to grow from USD 7.80 billion in 2022 to USD 10.62 billion by 2029, exhibiting a CAGR of 4.5%…

In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNAInitial…

SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster…

1. Hepatitis B is more common than you thinkHepatitis B is a viral infection and the leading cause of liver cancer worldwide². If left untreated, hepatitis B could be fatal. In fact, one in four individuals with hepatitis B could die from…

New York, Feb. 16, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Travel Vaccines Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Hepatitis A, Hepatitis B, Meningococcal…

– Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV – SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first…

SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been…

LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company…